End Stage Renal Disease. Enrollees who are identified by CMS as having ESRD after enrollment are not required to disenroll from the MCO’s SNBC product. Individuals who develop ESRD while enrolled in a health plan (e.g., a commercial or group health plan, or a Medicaid plan) offered by the MCO are eligible to elect the Medicare Advantage plan offered by that MCO. In order to be eligible, there must be no break in coverage between enrollment in the MCO, and the start of coverage in the Medicare Advantage plan offered by the same MCO. An individual who elects the SNBC SNP plan and who is medically determined to first have ESRD after the date on which the enrollment form is signed (or receipt date stamp if no date is on the form), but before the effective date of coverage under the SNBC SNP plan is still eligible to elect the SNBC SNP plan. See section 4.25 for ESRD Payments.
End Stage Renal Disease. Dialysis Treatment of end stage renal failure by dialysis. Dialysis is to be rendered by a Medicare- certified Dialysis facility.
End Stage Renal Disease. (ESRD). Enrollees who are identified by CMS as having ESRD after enrollment in MnDHO are not required to disenroll from the MCO’s MnDHO product.
End Stage Renal Disease. Renal Failure (End stage renal disease) presented as chronic irreversible failure of both kidneys to function, as a result of which either regular renal dialysis (hemodialysis or peritoneal dialysis) is instituted or renal transplantation is carried out. Diagnosis has to be confirmed by a specialist.
End Stage Renal Disease. Despite more efficacious treatments for lupus nephritis, the incidence of End- Stage Renal Disease (ESRD) has not decreased over the past 15 years, possibly due to patients not receiving appropriate care or receiving care too late in the progression of lupus nephritis [14]. In fact, some research has indicated that the incidence has actually increased [8, 14]. Overall, 20 to 25% of patients with lupus nephritis will develop ESRD [15]. Four to 20% of patients will develop ESRD within 10 years of the onset of lupus nephritis [14, 16]; 10 to 30% patients will develop ESRD within 15 years of the onset of lupus nephritis [17]. African Americans about nine times more likely to progress to ESRD compared to Whites [10]. ESRD requires more aggressive treatments (i.e. dialysis and transplantation). ESRD also carries an increased risk of mortality because of dialysis wait times, waiting list for kidney donors, and graft failure after transplantation. Nevertheless, as with other causes of ESRD, kidney transplantation has been associated with reduced mortality and improved quality of life [8]. Several factors may influence the progression to ESRD: greater number of ACR diagnostic criteria, younger age, minority groups, Fcγ genotype, barriers to care, comorbidities such as hypertension, and greater accrued renal damage, which can be identified by renal biopsies [14, 18].
